NCT05057715View on ClinicalTrials.gov

huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

March 2, 2022

Primary Completion Date

September 30, 2038

Study Completion Date

September 30, 2038

Conditions

Pancreatic CancerSerous Ovarian Cancer

Interventions

BIOLOGICAL

VCN-01

Intravenous administration of VCN-01

BIOLOGICAL

huCART-meso Cells

Intravenous administration of huCART-meso cells

Trial Locations (1)

19104

University of Pennsylvania, Philadelphia

Sponsors

Collaborators (1)

Theriva Biologics

All Listed Sponsors

collaborator

Theriva Biologics

UNKNOWN

lead

University of Pennsylvania

OTHER